The Vigi Awards: Recognizing Users Who Are Transforming Their Health Systems


The Vigi Awards were established with two primary goals in mind: 1) to recognize our customers whose clever use of the VigiLanz platform has helped their health systems make more informed decisions that optimize patient care, and 2) to showcase those customers’ stories and best practices with other customers.

This year, ten winners were chosen between the categories of Infection Prevention and Pharmacy Surveillance, recognizing forward-thinking individuals or teams who:

  • Place patient care first
  • Think outside the box and use VigiLanz to solve a unique problem
  • Leverage VigiLanz for cross-departmental initiatives

Each Vigi Award winner was recognized with a $1,000 donation to a charity of their choice.

Adventist Health System

Bringing 21 Hospitals to National Standards–and Reducing Annual Antibiotic Costs by $500K

After significantly improving the use of VigiLanz with rule refinement at Adventist Health + Rideout, Brock Taylor, PharmD, led the charge in expanding VigiLanz to an additional 19 hospitals in the Adventist Health System.

Following the platform’s introduction, the system saw significant outcomes in the areas of antibiotic utilization, infection prevention and cost savings.

“[Prior to Taylor’s efforts,] antibiotic use was in the top quartile of all hospitals. Implementation of 3-day and 7-day ‘timeout’ reviews—identification of mismatched antibiotics to cultures—the focus on use of Zosyn in non-pseudomonas infections reduced annual antibiotic expenses by $500,000. The hospital is now meeting national standards of antibiotic utilization.” – Jerry Gonzales, PharmD | Director of Pharmacy at Adventist Health + Rideout

See more results

Houston Methodist The Woodlands Hospital

From Inconsistent to Cost-Cutting: De-escalating Antibiotics and Validating Patient Safety

Following patient safety concerns regarding how positive cultures were handled after patient discharge, Houston Methodist The Woodlands Hospital formed a cross-departmental initiative to better communicate these results to both patient and provider.

Using VigiLanz’s microbiology reporting capabilities, the team developed an Inpatient Positive Cultures Report, which allowed the Infection Control Practitioner and Director of Infectious Disease to monitor culture collection dates, discharge dates, sensitivity results and physician information. After months of closely monitoring the Inpatient Positive Cultures Reports, the team was able to validate the hospital’s EMR to automate all communications for physicians, enabling them to ensure appropriate treatment.

“The speed and knowledge of VigiLanz report creation and customer support allowed us to make rapid improvements in our patient safety.” – Lindsey Brucchaus, MSN, RN, CPHQ | Infection Control Practitioner, Houston Methodist The Woodlands

As a result of the team’s work, the hospital has cut costs by de-escalating antibiotics and automating the microbiology follow-up process, and met targets for length of stay, all while validating and ensuring patient safety. Since introducing the initiative throughout the entire system, Houston Methodist has seen positive outcomes in the communities that their seven hospitals serve.

See more results

Antelope Valley and VigiLanz: Increasing Cost-Savings Enterprise Wide

Customer Profile

Antelope Valley Hospital (AVH), a 420-bed district hospital located in Lancaster, California, has been serving northern Los Angeles County for more than 60 years. The area’s only full-service acute-care hospital, AVH provides a full array of medical and surgical services, mental health services, cancer care, and more. It is a Level II trauma center, accredited chest pain center, advanced primary stroke center and comprehensive community cancer center.


Hospitals and health systems across the country consistently seek methods to improve patient care and reduce costs due to an increased focus on value-based care and fee transparency. For Antelope Valley, that meant looking at the hospital’s pharmacy department and implementing a system that would go beyond cost savings and efficiency within this one department.

“There came a point when we were advancing services, staffing and activity that we were somewhat limited in what we could do, like running reports,” explained Jill Bennett, PharmD, BCPS, Clinical Coordinator, Antelope Valley Hospital. “[Our current system] really only enabled us to look at a certain subsection of our population and only provided a snapshot of activities throughout the day. It was limiting.”

Bennett and her staff needed to make a change to accurately capture their entire patient population and intervene as needed. The team moved through several different systems. While it was more than what most hospitals had at the time, AVH needed more. It required a solution that had a dedicated rules engine, 24-hour surveillance and the ability to grow beyond pharmacy. After researching multiple platforms, the decision was clear: It had to be VigiLanz.

VigiLanz empowered the team to automatically screen and monitor every patient, while streamlining dosing, testing and reporting—and appropriately intervene and adjust treatment per a patient’s tailored therapy.


Antelope Valley Hospital initially implemented VigiLanz to condense product line software in the hospital and assist with adverse drug reaction reporting (ADR) and medication safety monitoring, but Bennett and her staff saw the data-sharing potential in the VigiLanz solution.

Thanks to data-sharing through the VigiLanz platform, Antelope Valley is able to utilize the platform as the primary source for ADR information and data storage, helping to eliminate more manual processes.

“The Electronic Health Record (EHR) does provide alerts for us at the point of order verification, which is where the pharmacist is typically working, but we don’t always have the time to address all of those things…we [also] don’t get as many rules, or the complexity of the rules that we do with VigiLanz at the point of order verification.”
— Jill Bennett, PharmD, BCPS, Clinical Coordinator, Antelope Valley Hospital

As the use of VigiLanz in the pharmacy department expanded, Bennett and her staff prepared to pull in other departments. The goal from the onset was to use VigiLanz to help solve issues related to antimicrobial stewardship, formulary compliance, Centers for Medicare and Medicaid Services (CMS) quality indicators, National Healthcare Safety Network (NHSN) reporting, and direct budget initiatives. It was a tall order, but VigiLanz delivered on it all.

Today, Antelope Valley also uses VigiLanz to submit antimicrobial stewardship data via NHSN AUR (only the AU piece currently) and perform data abstraction and submission as part of the Public Hospital Redesign and Initiatives in Medi-Cal (PRIME) program in California. For the PRIME metrics, it assists Antelope Valley in the data abstraction for perioperative prophylactic antibiotics administered after surgical closure and captures a variation on the metrics of the National Quality Forum 2720: National Healthcare Safety Network Antimicrobial Use Measure, primarily focused on the MRSA drugs and antipseudomonal beta-lactams. This offers Antelope Valley the ability to track and assist in improving these metrics and provides an opportunity to recover funds.

The problem-solving doesn’t stop there. Bennett also works as a VigiLanz champion to engage other departments and show the solution’s ability to generate reports in a variety of settings.

“We wanted to pull dietary into the loop. Early on, I gave [the department] ways that they would be able to follow patients that were either on TPNs or warfarin. I’ve also reached out to respiratory services about monitoring isolation patients, respiratory orders or sputum cultures,” added Bennett. “Nursing has also used it, particularly related to patient education and anticoagulation and the tracking mechanism, so they have a report set up that they are using.”


With the help of VigiLanz, Antelope Valley staff can now create more accurate reports and utilize them more effectively, streamlining workflow and optimizing patient outcomes. VigiLanz’s ability to function at the enterprise level has allowed Antelope Valley to rededicate resources to other care improvement initiatives. It has also streamlined compliance with federal and state requirements, while generating financial rewards in the form of recovered funds from programs like PRIME that can be reinvested into the hospital.

Another core target for Antelope Valley was improvement related to antimicrobial stewardship. Its clinical pharmacists used VigiLanz to reduce illness by increasing the capture of grouped antimicrobial-related interventions, and their sum of cost savings went from $2.8 million in 2016 to more than $3.6 million in 2017. With intervention on the fired alerts and an increased focus on stewardship rounding, Antelope Valley has progressively eliminated inappropriate use and reduced its antimicrobial days of exposure per days present (risk for antimicrobial exposure per time unit of analysis stratified by location). A facility-wide analysis is also calculated and has improved.

Adverse event avoidance documentation capture in 2016 as a sum of cost savings totaled more than $576,232, and in 2017 it was $474,064, a rather significant contribution that is likely underestimated in terms of harm avoided and costs incurred. In the last two years, the Emergency Department alone documented more than $100,000 in savings.

Bennett acknowledges that there is still work to be done, but hopes exercises in cost-savings, interventions and reporting will show hospital leadership that the VigiLanz investment is—and will continue to be—an investment in themselves and the patients they serve.

“I’ve always said that pharmacy is the only department in the hospital that can actually save you money…the value derived from VigiLanz supports that.”
— Jill Bennett, PharmD, BCPS, Clinical Coordinator, Antelope Valley Hospital

Tri-City Medical Center and VigiLanz: Achieving a Middleware First Through VigiLanz Connect

Customer Profile

Located in Oceanside, California, Tri-City Medical Center has served its community for over 50 years and is a 388-bed full service, acute-care hospital, with a primary care clinic and over 700 physicians practicing in 60 specialties. Its Gold Seal of Approval® from the Joint Commission recognizes its commitment to safe and effective patient care for the residents of the community it serves. It operates the only Level III Neonatal Intensive Care Unit (NICU) in North County, as well as an Orthopedic & Spine Institute, a Cardiovascular Health Institute and a Neuroscience Institute along with the Tri-City Wellness Center in Carlsbad, California, recognized as one of the best wellness centers in San Diego County. It also specializes in women’s health, robotic surgery, cancer and emergency care.


In the age of value-based care, it’s all about performance. Hospitals continually face increased financial pressure to reduce length of stay, hospital-acquired infection rates and hospital readmissions. The organization must improve healthcare analytics and core measures, avoid penalties and secure reimbursement, so it can continue to grow and thrive. This shift means hospitals must now consider cost avoidance instead of expecting direct reimbursement for patient care.

The challenge becomes how to support and enable next-generation healthcare providers to deliver real-time results from disparate platforms and technology. Sixty-two percent of hospital CIOs identify interoperability as a top priority, and 80 percent of accountable care organizations also cite data integration as a top challenge for their IT departments.

To help more healthcare providers deliver real-time results and to improve interoperability, medical facilities like Tri-City Medical Center require a services-oriented architecture and open application programming interface (API). The API must enable efficient aggregation, interaction and exchange of disparate data throughout the healthcare enterprise and across any of its software technologies, including EMRs and third-party single-point-solution vendors.


APIs fit the bill by allowing access to all of the data a digital health application and a health system would need in real time. Clinicians and administrators can now rapidly integrate new clinical and business information for better decision-making and, most importantly, for improved patient care with new interoperability services.

Tri-City Medical Center is the first VigiLanz customer site to utilize the company’s middleware API solution, VigiLanz Connect, to convert health data from its EMR into uniform, actionable intelligence in the VigiLanz Platform. Through VigiLanz Connect, the hospital turns its closed EMR systems into open platforms through robust services that do not rely on HL7 interfaces. VigiLanz handles connectivity and normalizes data structures across major EMR platforms, including Tri-City Medical Center’s Cerner platform, to quickly unlock the data. Benefits include shorter integration time (from months to days), elegant workflows, decreased maintenance costs and minimized risk.

“An API is definitely the way to go. Not only are APIs easy to use, but they are a no-brainer when it comes to rapid and successful implementation. Using VigiLanz’s middleware API helped us maximize the platform in a different, modern way. It is a simpler effort than using a solution like HL7, and it’s also stable and steady so it’s easy to maintain, despite the significant amount of data being pulled.” – Mark Albright, Vice President of Technology, Tri-City Medical Center

A middleware architecture has been shown to be the best technological solution for addressing the problem of EMR interoperability. The middleware platform facilitates the transparent, yet secure, access of patient health data directly from the various databases where it is stored. A hospital like Tri-City Medical Center no longer has to do all of the development itself. Instead, it can rely on off-the-shelf applications to solve problems. Middleware brings an application-agnostic approach to connecting EMRs to one another while allowing for specific development to enhance the significant investment by hospitals, health systems and physicians.

Palomar Health Leverages VigiLanz to Enhance Rapid Diagnostics for Antibiotic Resistance

Back Story

A healthcare system with breadth and depth

Palomar Health is a comprehensive healthcare system providing a full spectrum of healthcare services to communities in an 850-square-mile region, and a trauma center that covers more than 2,200 square miles of South Riverside and North San Diego County, the largest hospital district in California. In addition to three state-of-the-art hospitals—the 288-bed Palomar Medical Center Escondido, 319-bed Palomar Medical Center Downtown Escondido and 107-bed Palomar Medical Center Poway—the health system offers home health care, surgery, skilled nursing, ambulatory care, behavioral health services, wound care, and community health education programs.

At the forefront of technology, Palomar Health leverages the latest in medical technology without losing sight of the personal side of healthcare. This approach is why Palomar Health is nationally recognized for providing the highest quality of clinical care and access to comprehensive services.


Fighting antibiotic resistance with rapid diagnostics

Antibiotic resistance is growing rapidly, with the Centers for Disease Control and Prevention reporting that at least 2 million people are infected with antibiotic-resistant bacteria each year, 23,000 die as a direct result, and many more die from associated complications. For hospitals, combating these “nightmare bacteria” requires, among other things, rapid diagnosis and appropriate treatment, and closely monitoring resistance patterns within the facility.

“With blood infections, time is life because if you’re not getting the right antibiotic, that bacterium will kill you. It will cause you to go from a regular medicine floor to the ICU, or to progress towards death,” said Mike Kruse, Palomar Health’s manager of Clinical Pharmacy Services. “Keep in mind that bacteria have growing resistance, so we need to know what it is because it’s not going to stay the same over time, nor is it going to be the same between one patient and another.”

But it’s not as simple as accelerating the process. The blood cultures required to identify the correct bacterium, and therefore treatment, typically take 2–3 days. Until then, clinicians can only make their best educated guess.


Determined to reduce the severity of antibiotic resistance, Palomar Health began using the VERIGENE® System to enable rapid diagnostics with the VERIGENE® Gram-Positive and Gram-Negative Blood Culture Tests. Performed directly on positive blood culture bottles, rapid diagnostics rely on simultaneous screening to quickly detect infectious pathogens and drug resistance markers. This speeds detection of certain bacteria that are responsible for some of the most challenging and deadly infectious diseases, such as methicillin-resistant Staphylococcus aureus (MRSA) and gram negative rods such as E. coli. “It’s not quite Star Trek medicine, but it’s exciting enough that you feel as though you’re seeing Star Trek beginning to happen,” said Kruse. “It’s nucleic acid testing and that means at the genetic level, we are looking for pieces of genes that actually tell us what that bacterium is. We are even looking for pieces of genes that tell us the code for antibiotic resistance.”

Like any new technology, though, clinician adoption is imperative to the success of rapid diagnostics. It’s not enough to push the information into the patient’s electronic medical record, or even to push an alert to the clinician at the point of care. It must also be acted upon quickly and appropriately.

“We’d not used rapid diagnostics yet, so you’re not going to have every single provider knowing what to do with the information, or they’re not seeing it fast enough. So, then, what’s the purpose of rapid if it’s not really making rapid decisions?” said Kruse. “That’s where VigiLanz comes in.”


Pair VERIGENE® with VigiLanz

Palomar Health had implemented the VigiLanz clinical surveillance platform approximately two years prior to adding rapid diagnostics. At the time, they sought a solution that would provide “a daily list of tasks for our pharmacists, but also let them tap into clinical decision support so that we could improve the care for our patients and find things that we would not otherwise have found,” said Kruse. “After we’d had it in place for about two years, that’s when we began to use it to innovate.”

Rapid diagnostics is a prime example of the innovation made possible by VigiLanz. There are approximately 30 different iterations of bacteria or resistance patterns identifiable by VERIGENE®. So Palomar Health’s pharmacy team worked closely with the VigiLanz team to build approximately 60 rules to match bacteria with antibiotics, as well as mismatch rules.


“In some cases, it’s just an optimization of therapy, for example an antibiotic might be covered but it’s the most expensive one, or it is one that will cause more side effects,” said Kruse. “But the ones we really worry about are complete non-coverage, where you have bacterium growing and the current antibiotics are not going to cover it at all. That’s what’s exciting when you tie together VERIGENE® and VigiLanz.”

VigiLanz Becomes First Clinical Intelligence Platform to Integrate Sanford Guide Infectious Disease Content

MINNEAPOLIS, MN and SPERRYVILLE, VA. – (September 26, 2017) – VigiLanz, a digital healthcare intelligence firm, and Antimicrobial Therapy Inc., publisher and developer of The Sanford Guide, announced today an exclusive partnership that brings together the market-leading clinical intelligence platform and the industry’s top digital infectious disease content. Doing so provides VigiLanz users with the critical next step in the clinical surveillance process—access to peer-reviewed recommendations on the latest treatments for improved patient outcomes.

The agreement with Sanford Guide, the most trusted name in the treatment of infectious disease, is just the latest in a string of achievements for VigiLanz. Most recently, its antimicrobial stewardship platform achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report from KLAS Research.

The VigiLanz clinical intelligence platform leverages real-time monitoring of thousands of patient care data elements to help improve medication safety, antimicrobial stewardship, infection prevention, quality and care management, and patient safety. Its state-of-the-art rules engine analyzes that data and pushes alerts to clinicians at the point of care when interventions and other actions are necessary, driving significant improvements in safety, efficiency, performance, and reimbursement.

“Integrating Sanford Guide content into this process answers the question, ‘What’s next in the antimicrobial de-escalation process?’ by giving clinicians and pharmacists convenient access to the latest clinician-designed treatment recommendations without having to exit the VigiLanz system,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “We are proud to provide our clients with access to The Sanford Guide’s exceptional content and clinical guidance, more so because we are the first and only clinical intelligence platform able to do so.”

Trusted by clinicians in more than 100 countries, The Sanford Guide is optimized to minimize time-to-answer while providing comprehensive guidance at the point of care. Edited by distinguished infectious disease experts from leading academic and clinical centers, Sanford Guide content provides comprehensive coverage of treatment options for infectious diseases, syndromes, and pathogens. Under the partnership agreement, VigiLanz clients will have access to the full suite of Sanford Guide digital infectious disease content.

With continually updated information based on the latest available evidence, focused anti-infective drug information, interactive dosing tables, and extensive links to references and related resources, The Sanford Guide provides actionable guidance that is accessible, concise, and reliable.

“This partnership with VigiLanz is the most unique collaboration our company has undertaken since its founding nearly 50 years ago. As we moved forward with ever more sophisticated digital offerings, it was imperative that the company we aligned with share our values and commitment to improving the quality of treatment through focused clinical guidance at the point of care. VigiLanz was that company,” said Sanford Guide CEO and Managing Editor Jeb Sanford. “Together we have created a product that fully integrates trusted clinical treatment recommendations with top-rated clinical surveillance tools. Our goal is to improve patient outcomes while minimizing technology burdens on providers.”

For more information on the VigiLanz-Sanford Guide partnership, visit VigiLanz in booth #226 or Sanford Guide in booth #710 during IDWeek 2017, taking place October 4-8 in San Diego, CA.

About Sanford Guide

Since 1969, Sanford Guide has been a leader in point-of-care recommendations for the treatment of infectious diseases. Widely used by pharmacists, physicians, physician assistants, and nurses, Sanford Guide helps to improve patient care by providing carefully curated recommendations based on the latest evidence. With over 1 million users worldwide, Sanford Guide takes pride in responsiveness to customers, the development of innovative solutions, and providing content that is unparalleled in quality and clinical applicability.

About VigiLanz

Founded in 2001, VigiLanz Corporation ( is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

Cincinnati Children’s: Ensuring Safe Antibiotic Utilization Among Pediatric Kidney Patients

Customer Profile

Ranked by U.S. News & World Report as one of the nation’s best children’s hospitals, the 629-bed Cincinnati Children’s Hospital Medical Center is a leading medical research institution and teaching hospital caring for children from across the globe. Established in 1883, the healthcare system’s 15,260 employees engage in 1.25 million patient encounters each year, including approximately 34,000 admissions and 103,000 emergency department visits.

Cincinnati Children’s comprises the Department of Pediatrics of the University of Cincinnati College of Medicine, offering comprehensive clinical services ranging from treatments for rare and complex conditions to well-child care. It is the third-highest recipient of research grants from the National Institutes of Health among pediatric institutions and is among just 7% of hospitals in the U.S. to have earned Magnet-designation (2013-2017) by the American Nurses Credentialing Center.



With a growing body of evidence associating acute kidney injury (AKI) with an increased risk for development of chronic kidney disease, end-stage renal disease and mortality, Cincinnati Children’s was determined to reduce rates of AKI among its pediatric inpatient population. Baseline data indicated that, on average, six inpatients each week developed AKI during or within a week of discontinuing a vancomycin course. Additional evidence also suggested that extended courses of vancomycin—which when used beyond four days for empiric courses creates potentially unnecessary exposure to a nephrotoxic medication—may have been unintended.

Thus, vancomycin utilization was a natural target as the healthcare system embarked upon its mission to reduce the risk of AKI in pediatric patients. Specifically, Cincinnati Children’s sought to:

  • Decrease episodes of acute kidney injury associated with vancomycin use.
  • Decrease vancomycin exposure.
  • Decrease prolonged courses of vancomycin.
  • Increase oversight and approval for prolonged vancomycin exposure.

Success would require a close partnership between pharmacists and physicians that would enable implementation of an innovative, multistep quality improvement program focused on reducing the risk of vancomycin-induced kidney injury in pediatric patients. It also necessitated implementation of surveillance, clinical decision support and reporting technology capable of triggering interventions and educating clinicians on best practices.


Integrated within an existing antimicrobial stewardship program (ASP) and AKI reduction efforts, a core team of pharmacists, physicians, the chief medical resident and a quality improvement expert identified key drivers and implemented interventions including standardized orders, improved medical record documentation and integration of new processes into normal workflow. This enabled a stepwise approach using “plan-do-study-act” cycles.

Cincinnati Children’s also deployed the VigiLanz ASP solution to automate key processes, including screening and monitoring patients. The cloud-based platform leverages data collected from Cincinnati Children’s electronic medical record, physician order entry, laboratory and pathology systems to monitor patients in real-time for drug interactions and ineffective or inappropriate antibiotics. When potential issues are identified, alerts are triggered to enable clinical pharmacists and other members of the care team to take appropriate action.


Leveraging VigiLanz helped Cincinnati Children’s to create a sustainable and scalable framework that guides appropriate and safe use of antimicrobials while also promoting the safe and effective use of other medications. By enabling the provision of enterprise-wide guidance on the use of vancomycin in a matter of minutes each day, the technology helped drive significant improvements. These included:

  • Decreasing AKI associated with vancomycin exposure to an average of 4 per week from a baseline average of 6 per week, with sustained efforts likely to prevent an estimated 100 cases of vancomycin-associated acute kidney injury per year.
  • Decreasing vancomycin exposure (days of therapy/1000 patient days) by 43%, putting Cincinnati Children’s below the 25th percentile from a baseline near the 50th percentile.
  • Decreasing instances of prolonged courses of vancomycin by 44% hospital-wide.
  • Increasing ASP/ID approval in courses of vancomycin greater than four days to an average of 95% from a baseline average of 53%.

Cincinnati Children’s efforts to reduce AKI were recognized by the Association of Health-System Pharmacists, which gave the health system its 2016 Award for Excellence in Medication Safety.

“…We believe we can decrease the potential downside by choosing antibiotics that are likely to be just as effective but have less risk of increasing antibiotic resistance,” said David Haslam, M.D., an infectious disease specialist who joined Cincinnati Children’s specifically to launch its ASP initiative. “…Some hospitals just say ‘you can’t use that drug.’ Our approach will be ‘you might want to consider [another drug].’ We hope physicians will view this as bringing a lot of potential benefit.”– Silva, Mary. “Finding the Balance.” Research Horizons. Winter 2014.

VigiLanz Achieves Top Rating for Overall Satisfaction in KLAS AMS Performance Report

MINNEAPOLIS – (Aug. 31, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today that its antimicrobial stewardship platform achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report from KLAS Research. In identifying VigiLanz as the market leader, KLAS cited the platform’s highly robust, fairly user-friendly platform, the strength of the firm’s partnerships with customers, and its dedication to providing the guidance necessary to ensure customizations meet end users’ needs.

“The key is real-time alerting, and Antimicrobial Stewardship has it. The system is able to alert clinicians to certain conditions, even when the physicians are at home having dinner. It is nice to get alerts when we aren’t in front of the EMR,” according to one VigiLanz customer.

To compile its report, KLAS conducted in-depth interviews with current customers of each participating vendor to better understand which antimicrobial stewardship (AMS) tools are helping to drive meaningful interventions and track internal metrics. Interviews also focused on how well users can customize rule sets and use antibiograms to meet organizations’ unique goals, as well as which vendors help customers optimize tools and prepare for future reporting requirements.

Writes KLAS, “Providers new to AMS programs highly value guidance and expertise from their vendors, and VigiLanz’s proactive support has driven their top overall satisfaction rating. Provider interest in VigiLanz has grown over the last few years, and customers receive strong guidance and expertise that ensures their success.”

VigiLanz, which had the highest number of customers interviewed by KLAS, excelled in a large number of the evaluation categories. Under performance indicators, 100% of users said they would buy the platform again and that VigiLanz kept all promises. The platform also exceeded the market average for functionality of its custom rules set and customizable antibiogram. It was also singled out for being farthest along the compliance reporting spectrum, delivering on the three basic fronts of making AMS data accessible within the system for reporting, communicating with customers about forthcoming regulations and actions underway to help them prepare, and automating reporting. Specifically, customers have access to reports that can be submitted directly to the National Healthcare Safety Network (NHSN).

Also noteworthy is that a significant majority of respondents were satisfied or extremely satisfied with the VigiLanz platform’s ability to track key internal metrics and with its optimization services. This is an important distinction because, as KLAS notes, “internal tracking is crucial to a good AMS program because it enables users to see trending and benchmarking data. It can be tricky to do well because data from many different sources must be aggregated, analyzed and made easy to digest. VigiLanz customers have strong customization abilities and highly value VigiLanz’s robust interfaces, which successfully pull in data from many areas.”

“As more healthcare organizations seek to automate the crucial AMS process, it is important to partner with a vendor that can provide a solution that is flexible, robust and backed by outstanding customer support,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “It is truly gratifying to know that our customers feel that VigiLanz is that solution.”

About KLAS

KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider’s voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. Follow KLAS on Twitter.

VigiLanz Platform Earns Meaningful Use Stage 3 Certification for Antimicrobial Use and Resistance Reporting

MINNEAPOLIS, Minn. – (March 6, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today that its antimicrobial stewardship platform has earned Meaningful Use Stage 3 (MU3) certification validating its ability to collect and properly report data around antimicrobial use and resistance. The company is one of the first to achieve Stage 3 certification for use by facilities enrolled in the National Healthcare Safety Network (NHSN) that are required to begin reporting Antimicrobial Use and Antimicrobial Resistance (AUR) data in 2018.

A new option for public health registry reporting under MU3, collection of AUR data is already underway in preparation for the 2018 reporting period. Participating facilities must submit monthly reports on anti-infective medications—antibiotics, anti-bacterials, antifungals, antivirals, antiprotozoals, etc.—that the Centers for Disease Control and Prevention (CDC) will use to gain a better understanding of how their use impacts antimicrobial resistance in hospitals and healthcare facilities. The AUR objective calls for reporting a full calendar year’s data on R1 Normative Antimicrobial Use Summary, Antimicrobial Resistance Event, and Antimicrobial Resistance Summary data to be reported using Clinical Documentation Architecture (CDA) formatting.

“Inappropriate antibiotic utilization and multidrug resistant organisms are among the deadliest threats confronting the healthcare system today. That is why it was so important to us to achieve MU certification for AUR data collection and reporting,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA, noting that drug resistant organisms alone infect 2 million people and claim 23,000 lives in the U.S. every year, while adding $34 billion to annual healthcare costs. “It lets us play an active role in addressing this dangerous and costly phenomenon.”

Submission of AUR data into the NHSN platform allows clinicians to benchmark their antibiotic usage and organism resistance data nationally to target areas of improvement.

VigiLanz spent six months working on updates to its platform in preparation for its certification application. As such, it can properly collect and report data in the CDA format retroactively to January 1, 2017. Any customer with Dynamic Antimicrobial Stewardship or Dynamic Pharmacy Surveillance modules that is currently sending electronic medication reconciliation data can take advantage of certification without the need for additional upgrades, and without incurring any additional costs. VigiLanz also has the means to assist clients not yet collecting this data, to do so retroactively.

Part of VigiLanz’ clinical intelligence platform, the antimicrobial stewardship solution leverages data collected from a hospital’s electronic medical record, physician order entry, laboratory and pathology systems to monitor patients in real-time for drug interactions and ineffective or inappropriate antibiotics. When potential issues are identified, alerts are triggered to enable clinical pharmacists and other members of the care team to take appropriate action.

Certification Information:

“This Health IT Module is 2015 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services.  This certification does not represent an endorsement by the U.S. Department of Health and Human Services.”

Product(s) Certified:

Dynamic Antimicrobial Stewardship
Dynamic Pharmacy Surveillance
VigiLanz Corporation
5775 Wayzata Boulevard, Suite 970 Minneapolis MN 55416
Contact: Stacy Pur, VP of Clinical Product Management
Phone: (855) 525-9078
Modules Tested: 170.315 (d)(1-3, 7); (f)(6); (g)(4,5)
Clinical Quality Measures tested: None
Additional software used: None
Holds Certificate No: 15.04.04.XXXX.Dyna.
Date Certified: 02/17/2017
Effective Date:  2015 Edition

Disclosure Statement:

This certified product-version requires a one-time implementation fee and an annual licensing fee. This certified product-version is certified to data export criteria 170.315(f)(6.) and can generate Antimicrobial Use and Resistance CDA reports in real-time however this monthly data is not available until the 4th of each month to allow time for facility information to finalize.

VigiLanz Experts Address Breakthrough Benefits From Real-Time and Predictive Clinical Intelligence at Becker’s Hospital Events

MINNEAPOLIS–(BUSINESS WIRE)–Healthcare experts from VigiLanz, a software and services firm delivering healthcare intelligence to more than 300 hospitals, addressed hospital leaders from across the nation on the topic of ”Bending the Outcome Curve in the Fight Against Sepsis with Real-Time and Predictive Clinical Intelligence” at the recent Becker’s Hospital Review 7th Annual Meeting in Chicago. VigiLanz also hosted a Becker’s webinar on the topic, with more than 230 healthcare professionals attending.

The Becker’s Hospital Review conference is a premier event in healthcare drawing more than 1500 executives and clinicians from hospitals including the Mayo Clinic, Cleveland Clinic, Advocate Healthcare, University of Chicago Medical Center and Phoenix Children’s Hospital. Nearly 90 hospital CEOs, CFOs and CIOs, along with leading health technology innovators, led educational sessions.

Read more at The Business Wire

VigiLanz Introduces Enhanced Care Management Solutions Development Services at HIMSS 2016

Robust, flexible capability to design custom cloud-based real-time solutions including discrete workflows, alerts, analytics, reports, etc.

Architecture solves patient care and delivery, readmission, reporting, and cost containment challenges, etc.

MINNEAPOLIS–(BUSINESS WIRE)–VigiLanz, an enterprise intelligence resources (EIR) software and services firm delivering real-time clinical and business intelligence services to approximately 400 hospitals, introduced today its enhanced Care Management Solutions development services at HIMSS ’16, the annual healthcare information technology conference and exhibition being held this year in Las Vegas.

VigiLanz Care Management Solutions delivers a robust, flexible configuration and customization environment that can be leveraged across a healthcare enterprise by administration, IT, patient care givers, hospital support staff, and researchers alike. “This ‘open platform-on-a-platform’ in the cloud enables numerous and varied projects to be configured and implemented quickly using VigiLanz Care Management Solutions Services for inpatient and outpatient populations alike,” said David Goldsteen M.D., VigiLanz chairman and CEO. “With VigiLanz Care Management Solutions, clients have a workbench environment on the VigiLanz Intelligence platform, to address specific problems by designing custom sets of services, including discrete clinical workflows, real-time alerting, analytics and reports. Groups that are dedicated to improving patient care, care delivery, readmission, cost containment and working to optimize research efficiencies can benefit greatly from the flexibility we provide.”

According to Stacy Pur, VigiLanz Clinical Intelligence vice president, workflows, alerts, analytics and reporting are significantly different from what a typical EHR transaction system can provide. “One of the major advantages of using VigiLanz Intelligence is the rapid speed, flexibility and responsiveness of our enterprise platform. VigiLanz Care Management Solutions enables the creation and delivery of numerous software-based services quickly to meet the dynamic and evolving needs of users. In addition, VigiLanz provides flexibility in working with many different types of healthcare and alternative data across a variety of user groups, and particularly offers the unique ability to standardize disparate data elements along with the ability to deliver solutions and services to groups and systems outside of typical EHR user groups.”

Read more at the Business Wire